1. Strokovna priporočila za obravnavo radiodermatitisa in radiomukozitisaSandra Gole, Martina Goličnik, Vesna Jašić, Andreja Klinc, Januša Marenk, Irena Oblak, Miha Oražem, Klemen Schara, Primož Strojan, Petra Šanc, Maja Trošt, Bernarda Ugovšek, 2026, strokovni članek Povzetek: Radioterapija predstavlja pomemben del sodobnega onkološkega zdravljenja, vendar pogosto povzroča neželene učinke na koži in sluznicah, med katerimi sta najpogostejša radiodermatitis in radiomukozitis. Namen strokovnih priporočil je poenotiti obravnavo bolnikov, izboljšati prepoznavanje zgodnjih sprememb ter podati priporočila za preprečevanje, ocenjevanje in zdravljenje teh zapletov. Dokument obravnava etiologijo, dejavnike tveganja, klinično sliko in stopnje radiodermatitisa ter radiomukozitisa glede na področje obsevanja. Poseben poudarek je namenjen preventivnim ukrepom, zdravstveni negi, prehranski podpori, obvladovanju bolečine ter multidisciplinarnemu pristopu pri obravnavi bolnikov med in po zdravljenju z radioterapijo. Priporočila so namenjena zdravstvenim delavcem in sodelavcem na vseh ravneh zdravstvenega varstva, ki sodelujejo pri vsakodnevni oskrbi onkoloških bolnikov
Ključne besede: radioterapija, radiodermatitis, radiomukozitis, onkološka zdravstvena nega, neželeni učinki zdravljenja
Objavljeno v DiRROS: 31.07.2026; Ogledov: 110; Prenosov: 41
 Celotno besedilo (464,77 KB) |
2. Impaired booster-induced SARS-CoV-2 antibody responses in rituximab-treated B-cell lymphoma patients despite peripheral B-Cell RecoveryTomaž Jurca, Lučka Boltežar, Miha Oražem, Kristina Fujs Komloš, Katka Pohar, Sara Jevnikar, Mario Poljak, Denis Mlakar-Mastnak, Nada Rotovnik-Kozjek, Bor Vratanar, Janja Ocvirk, Alojz Ihan, 2026, izvirni znanstveni članek Povzetek: Rituximab-treated patients with B-cell lymphoma exhibit profound B-cell depletion and impaired vaccine-induced antibody responses. However, it remains uncertain whether recovery of peripheral B-cell counts after rituximab is sufficient to restore effective humoral immunity following booster vaccination. Patients and methods In this prospective, single-center observational study at the Institute of Oncology Ljubljana, adult B-cell lymphoma patients treated with or previously exposed to rituximab received the Comirnaty® mRNA COVID-19 vaccine. Antibody responses to the SARS-CoV-2 spike and nucleoprotein were measured at baseline, 14 days after the second dose, and at 3, 6, 9, and 12 months. A third dose was administered at 6 months. T-cell responses (IFN-γ release) were assessed in patients before and after the primary series and booster dose. Lymphocyte subsets were analysed pre-vaccination. Adverse events and nutritional status were monitored. Results Patients undergoing anti-CD20 therapy showed absent antibody responses. Longer intervals since rituximab correlated with peripheral B-cell repopulation. However, even after reaching normal B-cell counts, patients’ antibody responses after revaccination remained significantly lower than in controls. Conclusions Rituximab is associated with impaired vaccine-induced antibody responses. Despite recovery of peripheral B-cell counts, patients with B-cell lymphoma show reduced humoral responses compared with healthy individuals following booster COVID-19 vaccination.
Ključne besede: lymphoma, B-cell, rituximab, COVID-19 vaccines
Objavljeno v DiRROS: 03.06.2026; Ogledov: 334; Prenosov: 119
Celotno besedilo (565,04 KB) |
3. |
4. Sequencing of chemotherapy in total neoadjuvant treatment for rectal cancer does not predict radiation-induced lymphopeniaMiha Oražem, Vaneja Velenik, Alojz Ihan, 2025, izvirni znanstveni članek Povzetek: Radiation-induced lymphopenia (RIL) is associated with an increased risk of death in solid tumors, including rectal cancer. The aim of this study was to determine whether the sequencing of chemotherapy in total neoadjuvant treatment (TNT) for rectal cancer predicts the development of RIL. Patients and methods We analyzed acute hematologic toxicity data from 53 patients who underwent TNT for locally or locoregionally advanced rectal cancer between July 2022 and April 2023. Twenty-eight patients received induction chemotherapy with capecitabine and oxaliplatin [CAPOX], and 25 received consolidation chemotherapy (6 cycles of CAPOX in both groups). The chemoradiation protocol consisted of Volumetric Modulated Arc Therapy with Simultaneous Integrated Boost Radiotherapy (VMAT-SIB RT) up to 48.4 Gy in 22 fractions, concomitantly with capecitabine twice a day (lat. bis in die, BID). The Mann-Whitney U test was performed to compare RIL between the two patient groups. Pelvic bone marrow was contoured as a non-limiting organ-at-risk to assess the received dose, and binary logistic regression was used to determine whether RIL depends on V5Gy~V42Gy or the planning target volume (PTV) size. Results Thirty-four patients (64.2%) developed RIL of any grade, which was not significantly associated with either the induction or consolidation chemotherapy TNT regimen (Wald = 3.159, p = 0.076). No significant differences were found in neutrophil counts or the neutrophil-to-lymphocyte ratio. In the logistic regression model predicting the likelihood of RIL, two variables were statistically significant: V10Gy (Wald = 4.366, p = 0.037) and V30Gy (Wald = 6.084, p = 0.014). These results indicate that V10Gy< 71% and V30Gy< 26.6% may reduce the likelihood of developing RIL. Conclusions In our study, the sequencing of chemotherapy in TNT for rectal cancer did not predict the development of RIL. However, the incidence of RIL may be reduced by applying RT dosimetric constraints to the pelvic bone marrow.
Ključne besede: radiation-induced lymphopenia, rectal cancer, total neoadjuvant treatment
Objavljeno v DiRROS: 26.11.2025; Ogledov: 857; Prenosov: 209
Celotno besedilo (508,29 KB) |
5. |
6. |
7. |
8. Obsevanje ginekoloških tumorjevBarbara Šegedin, Helena Barbara Zobec Logar, Manja Šešek, Ana Perpar, Blaž Grošelj, Miha Oražem, 2023, strokovna monografija Ključne besede: teleterapija, brahiterapija, prehrana, kemoterapija, stranski učinki
Objavljeno v DiRROS: 22.11.2023; Ogledov: 2455; Prenosov: 599
Celotno besedilo (1,18 MB) |
9. |
10. |
